Clinical characteristics and prognosis of community-acquired pneumonia in autoimmune disease-induced immunocompromised host: A retrospective observational study

被引:0
|
作者
Zhong-shu Kuang [1 ]
Yi-lin Yang [1 ]
Wei Wei [1 ]
Jian-li Wang [1 ]
Xiang-yu Long [1 ]
Ke-yong Li [2 ]
Chao-yang Tong [1 ]
Zhan Sun [1 ]
Zhen-ju Song [1 ]
机构
[1] Department of Emergency Medicine, Zhongshan Hospital, Fudan University
[2] Department of Pharmacology, University of Virginia School of Medicine Charlottesville
基金
中国国家自然科学基金;
关键词
Community-acquired pneumonia; Immunocompromised hosts; Autoimmune disease; Prognostic marker;
D O I
暂无
中图分类号
R593.2 [自身免疫性疾病、结缔组织疾病]; R563.1 [肺炎];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Community-acquired pneumonia(CAP) in autoimmune diseases(AID)-induced immunocompromised host(ICH) had a high incidence and poor prognosis. However, only a few studies had determined the clinical characteristics of these patients. Our study was to explore the characteristics and predictors of mortality in CAP patients accompanied with AID-induced ICH. METHODS: From 2013 to 2018, a total of 94 CAP patients accompanied with AID-induced ICH, admitted to Emergency Department of Zhongshan Hospital, Fudan University, were enrolled in this study. Clinical data and the risk regression estimates of repeated predictors were evaluated by generalized estimating equations(GEEs) analysis. An open-cohort approach was used to classify patient’s outcomes into the survival or non-survival group.RESULTS: The hospital mortality of patients with CAP occurring in AID-induced ICH was 60.64%. No significant differences were found with respect to clinical symptoms and lung images between survival and non-survival groups, while renal insufficiency and dysfunction of coagulation had higher proportions in non-survival patients(P<0.05). Both noninvasive ventilation(NIV) and invasive mechanical ventilation(IMV) were performed more frequently in non-survival group(P< 0.05). By the multivariate GEEs analysis, the repeated measured longitudinal indices of neutrophilto-lymphocyte ratio(NLR)(odds ratio [OR]=1.055, 95% confidence interval [95%CI] 1.025–1.086), lactate dehydrogenase(LDH)(OR=1.004, 95%CI 1.002–1.006) and serum creatinine(s Cr)(OR=1.018, 95%CI 1.008–1.028), were associated with a higher risk of mortality. CONCLUSION: The CAP patients in AID-induced ICH had a high mortality. A significant relationship was demonstrated between the factors of NLR, LDH, s Cr and mortality risk in these patients.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 50 条
  • [1] Clinical characteristics and prognosis of community-acquired pneumonia in autoimmune disease-induced immunocompromised host: A retrospective observational study
    Kuang, Zhong-shu
    Yang, Yi-lin
    Wei, Wei
    Wang, Jian-li
    Long, Xiang-yu
    Li, Ke-yong
    Tong, Chao-yang
    Sun, Zhan
    Song, Zhen-ju
    WORLD JOURNAL OF EMERGENCY MEDICINE, 2020, 11 (03) : 145 - 151
  • [2] Clinical characteristics and prognosis of community-acquired pneumonia in autoimmune disease-induced immunocompromised host: A retrospective observational study
    Zhongshu Kuang
    Yilin Yang
    Wei Wei
    Jianli Wang
    Xiangyu Long
    Keyong Li
    Chaoyang Tong
    Zhan Sun
    Zhenju Song
    World Journal of Emergency Medicine, 2020, 11 (03) : 145 - 151
  • [3] Community-Acquired Pneumonia in the Immunocompromised Host: Epidemiology and Outcomes
    Ramirez, Julio A.
    Chandler, Thomas R.
    Furmanek, Stephen P.
    Carrico, Ruth
    Wilde, Ashley M.
    Sheikh, Daniya
    Ambadapoodi, Raghava
    Salunkhe, Vidyulata
    Tahboub, Mohammad
    Arnold, Forest W.
    Bordon, Jose
    Cavallazzi, Rodrigo
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (11):
  • [4] Clinical characteristics and outcomes of immunocompromised patients with severe community-acquired pneumonia: A single-center retrospective cohort study
    Wu, Xiaojing
    Sun, Ting
    Cai, Ying
    Zhai, Tianshu
    Liu, Yijie
    Gu, Sichao
    Zhou, Yun
    Zhan, Qingyuan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [5] A clinical pathway for community-acquired pneumonia: an observational cohort study
    Christopher R Frei
    Allison M Bell
    Kristi A Traugott
    Terry C Jaso
    Kelly R Daniels
    Eric M Mortensen
    Marcos I Restrepo
    Christine U Oramasionwu
    Andres D Ruiz
    William R Mylchreest
    Vanja Sikirica
    Monika R Raut
    Alan Fisher
    Jeff R Schein
    BMC Infectious Diseases, 11
  • [6] A clinical pathway for community-acquired pneumonia: an observational cohort study
    Frei, Christopher R.
    Bell, Allison M.
    Traugott, Kristi A.
    Jaso, Terry C.
    Daniels, Kelly R.
    Mortensen, Eric M.
    Restrepo, Marcos I.
    Oramasionwu, Christine U.
    Ruiz, Andres D.
    Mylchreest, William R.
    Sikirica, Vanja
    Raut, Monika R.
    Fisher, Alan
    Schein, Jeff R.
    BMC INFECTIOUS DISEASES, 2011, 11
  • [7] Early identification of severe community-acquired pneumonia: a retrospective observational study
    Grudzinska, Frances S.
    Aldridge, Kerrie
    Hughes, Sian
    Nightingale, Peter
    Parekh, Dhruv
    Bangash, Mansoor
    Dancer, Rachel
    Patel, Jaimin
    Sapey, Elizabeth
    Thickett, David R.
    Dosanjh, Davinder P.
    BMJ OPEN RESPIRATORY RESEARCH, 2019, 6 (01)
  • [8] Community-Acquired Pneumonia in the Immunocompromised Patients: An Observational Study from a Single Center, TURKEY
    Yilmaz, Ezgi
    Benli, Aysun
    Basaran, Seniha
    Simsek-Yavuz, Serap
    Cagatay, Atahan
    Oncul, Mustafa Oral
    Ozsut, Halit
    Eraksoy, Haluk
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 4875 - 4885
  • [9] Comparison of clinical characteristics between coronavirus disease 2019 pneumonia and community-acquired pneumonia
    Tian, Juncai
    Xu, Qizhong
    Liu, Song
    Mao, Lingli
    Wang, Maoren
    Hou, Xuewen
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (11) : 1747 - 1752
  • [10] Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort
    Akihiro Ito
    Tadashi Ishida
    Hironobu Tokumasu
    Yasuyoshi Washio
    Akio Yamazaki
    Yuhei Ito
    Hiromasa Tachibana
    BMC Pulmonary Medicine, 17